Clinical Trials Logo

Clinical Trial Summary

This is a Phase II pilot study to explore the effect of intravesical TMX-101 in patients with CIS bladder cancer, as assessed by histology and cytology after TMX-101 treatment.


Clinical Trial Description

This study is an open label, pilot study of TMX-101 in the treatment of carcinoma in situ. TMX-101 is a new formulation of Imiquimod optimized for intravesical delivery. Imiquimod possesses immune-stimulatory properties. TMX-101 is being developed as a potential treatment for patients with non-invasive bladder cancer, including patients with CIS bladder cancer.

Following confirmation of CIS by histology, patients will receive weekly instillations of TMX-101 for 6 weeks. Five to seven weeks after the last instillation, biopsies and cytology will be performed. Response to treatment will be determined based on cytology and tissue sample histology findings. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01731652
Study type Interventional
Source Telormedix SA
Contact
Status Completed
Phase Phase 2
Start date February 2013
Completion date October 2014

See also
  Status Clinical Trial Phase
Recruiting NCT06022029 - A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. Phase 1
Recruiting NCT02402244 - Project: Every Child for Younger Patients With Cancer
Active, not recruiting NCT03223753 - Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Phase 3
Completed NCT02039388 - Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma N/A
Terminated NCT01200992 - Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer Phase 3
Completed NCT01316874 - Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) Phase 2/Phase 3
Completed NCT04823871 - Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing N/A
Recruiting NCT06056843 - Handheld Ultrasound Device to Triage Women With a Positive Clinical Breast Examination by Trained Non-radiologists N/A
Terminated NCT01310803 - Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder Phase 3
Terminated NCT01438112 - Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Phase 2/Phase 3
Completed NCT03268993 - Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer N/A
Completed NCT04312737 - Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
Recruiting NCT02858310 - E7 TCR T Cells for Human Papillomavirus-Associated Cancers Phase 1/Phase 2
Completed NCT01901991 - Localization of Nonpalpable Breast Lesions N/A
Completed NCT02217358 - Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions N/A
Recruiting NCT05014139 - A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) Phase 1
Withdrawn NCT02698293 - PDT Plus Vitamin D3 for Anal Dysplasia Phase 1
Completed NCT03808818 - Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices Phase 2
Completed NCT03182959 - Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer Early Phase 1